Applied DNA Sciences announced a strategic shift to focus exclusively on synthetic DNA manufacturing through its LineaRx subsidiary. The company ceased operations at its molecular and genetic testing lab, laying off 27% of staff to reduce costs. CEO Judy Murrah emphasized concentrating resources on expanding LineaRx's platforms, including LineaDNA and LinealVT, which cater to nucleic acid therapy manufacturing. The move aims to improve operational efficiency amid a cash balance of approximately $4.8 million.